International Journal of Hematology

, Volume 92, Issue 5, pp 762–764

Interferon-α and zidovudine for relapsed/refractory adult T cell leukemia/lymphoma: case reports of Japanese patients

Authors

    • Division of Medical Oncology, Hematology and Infectious DiseaseFukuoka University
  • Hiroo Katsuya
    • Division of Medical Oncology, Hematology and Infectious DiseaseFukuoka University
  • Tomona Toyota
    • Division of Medical Oncology, Hematology and Infectious DiseaseFukuoka University
  • Masanao Ishizu
    • Division of Medical Oncology, Hematology and Infectious DiseaseFukuoka University
  • Naoko Kunami
    • Division of Medical Oncology, Hematology and Infectious DiseaseFukuoka University
  • Mana Fujita
    • Division of Medical Oncology, Hematology and Infectious DiseaseFukuoka University
  • Hidenori Sasaki
    • Division of Medical Oncology, Hematology and Infectious DiseaseFukuoka University
  • Yasushi Takamatsu
    • Division of Medical Oncology, Hematology and Infectious DiseaseFukuoka University
  • Masanobu Uchiyama
    • Department of PharmacyFukuoka University Hospital
  • Haruo Fujikane
    • Department of PharmacyFukuoka University Hospital
  • Kentaro Ogata
    • Faculty of Pharmaceutical SciencesFukuoka University
  • Shuuji Hara
    • Faculty of Pharmaceutical SciencesFukuoka University
  • Kazuo Tamura
    • Division of Medical Oncology, Hematology and Infectious DiseaseFukuoka University
Case Report

DOI: 10.1007/s12185-010-0717-3

Cite this article as:
Ishitsuka, K., Katsuya, H., Toyota, T. et al. Int J Hematol (2010) 92: 762. doi:10.1007/s12185-010-0717-3

Abstract

Combination therapy with interferon-α and zidovudine (IFN/AZT) has been regarded as standard care for acute and indolent (i.e., chronic and smouldering) ATL based on reports involving a limited number of patients. This treatment approach has not been evaluated in Japan, a major endemic area of this disease in the world. This is the first Japanese report of IFN/AZT for ATL. It is impossible to draw any definitive conclusion from this small study; however, IFN/AZT showed clear anti-ATL effects for refractory/relapsed ATL patients. This report would contribute for developing future ATL treatment in Japan.

Keywords

ATLInterferonZidovudine

Copyright information

© The Japanese Society of Hematology 2010